Moderna (MRNA.US) announced that the 2019 coronavirus mRNA vaccine formula developed for the SARS-CoV-2 JN.1 variant, 'Spikevax,' has arrived in Hong Kong this week and will be available for vaccination at designated locations by the Hong Kong government starting next Monday (25th).

Lu Minyi, General Manager of Moderna in Hong Kong, stated that as the new crown peak approaches, it is crucial to administer the latest vaccines. The company also plans to introduce more treatment solutions developed using messenger ribonucleic acid (mRNA) technology to contribute to improving the local medical system.